
FDA grants accelerated approval to tazemetostat for follicular lymphoma
The Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for…
The Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for…
The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for the treatment…
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly…